Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus (ClearMEMory)

Vanderbilt University Medical Center logo

Vanderbilt University Medical Center

Status and phase

Enrolling
Phase 2

Conditions

Lupus Erythematosus, Systemic

Treatments

Drug: Memantine
Drug: Placebo

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT03527472
180256

Details and patient eligibility

About

A phenome-wide association study (PheWAS) identified an association between a variant in the human gene for the N2A subunit of the N-methyl-D-aspartate (NMDA) receptor, GRIN2A, and Systemic Lupus Erythematosus (SLE). A single nucleotide polymorphism (SNP) in this gene encodes for increased NMDA receptor activity. Based on the potential function of the associated SNP and published literature, alterations in SNP function signaling may underlie a cluster of symptoms. The objective of this study is to evaluate the safety, tolerability and efficacy of memantine, an NMDA receptor antagonist, in a precise patient subset with SLE. Participants will complete a full 14-week clinical trial, receiving either memantine or a placebo. Participants' blood will be drawn to test for various antibodies as well as organ function. Patients' urine will also be collected to assess organ function and pregnancy for females at a number of specific time points. The overall goal is to develop a safe and inexpensive therapeutic approach to reduce debilitating cognitive symptoms in a precisely selected SLE sub-population.

Enrollment

80 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Meet American College of Rheumatology (ACR) criteria for SLE
  2. Report NPSLE symptoms on the screening survey recommended by EULAR guideline but limited to the psychiatric manifestations questions
  3. Score ≤ 85 on the RBANS total index (≤ 1 SD below the normative mean of 100)

Exclusion criteria

  1. Male and female subjects <18 or >60 years
  2. Change in medication that may affect mood or cognition including prednisone, antidepressant medications, or stimulants within the last 4 weeks
  3. Regular (daily) use of opioids or other drugs of abuse including heavy alcohol or marijuana use
  4. Metabolic derangement defined as liver function tests >3x upper limit of normal or severe renal disease defined as calculated creatinine clearance <30 mL
  5. Severe psychiatric disease including schizophrenia, psychosis, suicidal depression
  6. Other factors which in the opinion of the investigator could potentially impact the study outcomes (e.g., underlying disease, medications, history)* or prevent the participant from completing the protocol (poor compliance or unpredictable schedule)
  7. Inability or refusal to give informed consent for any reason including a diagnosis of dementia or significant cognitive impairment**
  8. Patients who are pregnant
  9. Patients who are enrolled in other investigational drug studies

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

80 participants in 2 patient groups, including a placebo group

Memantine
Experimental group
Description:
At randomization, subjects will receive 5 mg twice per day for one week. They will escalate their dose to 10 mg twice per day for one week, then 10 mg in the morning and 20 mg at night for one week, and finally 20 mg twice per day for three weeks. Maximum tolerated will be determined at this time and this dose will be continued for an additional six weeks.
Treatment:
Drug: Memantine
Placebo
Placebo Comparator group
Description:
At randomization, subjects will receive one matching placebo capsule twice per day for one week. They will also take one matching placebo capsule twice per day for the next week (week 2), then one matching placebo capsule in the morning and two capsules at night for one week (week three), and finally two capsules twice per day for three weeks (weeks 4-6). Maximum tolerated number of capsules will be determined at this time and this dose will be continued for an additional six weeks.
Treatment:
Drug: Placebo

Trial documents
1

Trial contacts and locations

3

Loading...

Central trial contact

Jillian P Rhoads, PhD; Jonathan M Williams, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems